Martin Drew

[BostonSci Cardiology @BSCCardiology]

Recent data from the AGENT™ DCB post-approval study demonstrates that AGENT DCB shows in-hospital safety outcomes comparable to DES in patients with ISR. This evidence reinforces clinical confidence in AGENT without compromising safety.

Learn more about the study: https://t.co/yAZfDhOPsT

AGENT™ Drug-Coated Balloon Indications, Safety, and Warnings: https://t.co/jZ1IfpGl7J

[Boston Scientific EMEA - Cardiology @BSC_EU_Heart]

Step into what’s next in Interventional Cardiology at #EuroPCR 2026. See how new evidence in #ModernPCI, LAAC and Pulmonary Embolism translates into real‑world practice.
Choose from 3 symposia and 50+ expert‑led sessions: https://t.co/6APIpJZqS9

#BSCEMEA

[BostonSci Cardiology @BSCCardiology]

OACs may present challenges for patients and the physicians who treat them. Are OACs worth the risk? Or is there a better option? WATCHMAN™ is the first and only #LAAC device to demonstrate non-inferior efficacy and superior safety profile to DOACs. ⁴

Break the pattern of OACs and provide stroke protection beyond the prescription. Learn more at https://t.co/HRX0ypd3dx

WATCHMAN FLX Pro Left Atrial Appendage Closure Device Indications, Safety, and Warnings: https://t.co/eV4ii0HuvR

[BCIS @BCIS_uk]

Registration is now OPEN for the AHP Annual Conference 2026 🎉

Join one of the UK’s largest dedicated meetings for nurses and allied health professionals working in the cath lab.

🔹 Core & Advanced learning streams
🔹 Hands-on demonstrations
🔹 Practical, team-focused education
🔹 Conference dinner included

Free for BCIS members
Accommodation bursaries are available for eligible attendees.
Be the first to register here: https://t.co/Y2YUXcId17

[BostonSci Cardiology @BSCCardiology]

Improved IVUS-guided PCI outcomes support critical clinical decisions.

In a recent publication, Dr. Simon Walsh outlines the IVUS 123 Workflow, a simplified, standardized approach designed to support intuitive decision-making, reproducibility, and long-term PCI durability.

📄Read more: https://t.co/A3H9tfj7Fw

[BCIS @BCIS_uk]

Good morning from #BCISACI Day Two in the Education Zone!

This morning, @jdinaus and @JenARossington are teaming up for the Boston Scientific Breakfast Symposium, Streamlining IVUS-Guided PCI Workflow: Driving Efficiency with ALA.

There is still time to join. The session is located in the Exhibition area on the 3rd Floor of the West Wing.

[BostonSci Cardiology @BSCCardiology]

The ShortCUT trial data shows that WOLVERINE™ Cutting Balloon™ demonstrated significant cost savings in total procedural costs compared to IVL.

See the cost comparison: https://t.co/RnGoVFKZSj

WOLVERINE Coronary Cutting Balloon Indications, Safety, and Warnings: https://t.co/yuhCef5MWq

[BostonSci Cardiology @BSCCardiology]

Designed with intent, AGENT™ DCB leverages Paclitaxel’s intrinsic properties — hydrophobic, lipophilic, and structurally optimized — to deliver drug efficiently and durably.

• Hydrophobic for minimized drug loss during delivery
• Lipophilic for rapid absorption into fatty tissue
• Sharp-edge structure for improved tissue penetration

Explore AGENT™ DCB: https://t.co/Wp9VctvbtS

AGENT™ Drug-Coated Balloon Indications, Safety, and Warnings: https://t.co/jZ1IfpGl7J

[BostonSci Cardiology @BSCCardiology]

Pre-clinical data showed that AGENT™ DCB’s sharp-edge Paclitaxel coating enabled deeper tissue penetration compared to ‘Limus DCB’s spherical coating morphology.

📊The result: improved drug delivery efficiency at the tissue level — achieved through design, not chance. Learn more about the science behind AGENT™ DCB: https://t.co/Wp9VctvbtS

AGENT™ Drug-Coated Balloon Indications, Safety, and Warnings: https://t.co/jZ1IfpGl7J

[BostonSci Cardiology @BSCCardiology]

AGENT™ DCB delivered 2.3x more drug into tissue than 'Limus DCB in pre-clinical testing, and also showed 67% fewer downstream particulates than 'Limus DCB in bench testing.

By pairing Paclitaxel’s hydrophobic, lipophilic properties with a sharp-edge structure, AGENT™ DCB delivers higher transfer and less downstream. See what makes AGENT™ DCB different: https://t.co/Wp9VctvbtS

AGENT™ Drug-Coated Balloon Indications, Safety, and Warnings: https://t.co/jZ1IfpGl7J

[BostonSci Cardiology @BSCCardiology]

See how imaging + vessel prep drive success in PCI with AGENT™ DCB. Top interventional cardiologists walk through key clinical cases. 🎥View the full case on EDUCARE: https://t.co/5UYNzDfkrI

AGENT™ Drug-Coated Balloon Indications, Safety, and Warnings: https://t.co/Gk5mQsY9pM

[BostonSci Cardiology @BSCCardiology]

Transforming PCI with #IVUS! Discover how it enhances patient outcomes and leads to higher long-term survival rates. 🔗 Explore our clinical data: https://t.co/KHuW3cG14L

[BostonSci Cardiology @BSCCardiology]

📢 The AGENT DCB STANCE Trial has commenced! This trial is designed to assess the safety and efficacy of AGENT™ Drug-Coated Balloon in de novo coronary lesions. Learn more: https://t.co/f4Vy7l9Xrv

CAUTION: Investigational Device in de novo lesions. Limited by Federal (or US) law to investigational use only. Safety and effectiveness has not been established in de novo lesions.

[Boston Scientific EMEA - Cardiology @BSC_EU_Heart]

Did you miss the Integration of CT and IVUS for Treatment of Coronary Artery Disease in Daily Practice at #EuroPCR 2025? Access the full replay
here: https://t.co/EjqLsLEkyu

@sbrugaletta demonstrated how CT imaging and IVUS can improve planning and execution of PCI.

[Boston Scientific EMEA - Cardiology @BSC_EU_Heart]

Precision Meets Innovation in Coronary Interventions
Watch Dr. Joost Daemen demonstrate AVVIGO™+ in a real-world case of LAD bifurcation in a 72-year-old patient.

Watch the full case on EDUCARE: https://t.co/pqDBT1esKk

#InterventionalCardiology #AVVIGO+ #PCI #EDUCARE #IVUS

[BostonSci Cardiology @BSCCardiology]

At #CRT2025, in study results from Dr. @hect2701 and team, automated IVUS-guided lesion assessment with AVVIGO™+ ALA™ demonstrated high concordance with experts. Learn more: https://t.co/jTipCeykJZ

Safety info: https://t.co/XvW51LQFu9

[Boston Scientific @bostonsci]

We have officially closed the acquisition of @BoltIVL. We look forward to advancing the intravascular lithotripsy (IVL) therapy developed by Bolt which will complement our cardiovascular portfolio by expanding treatment options for coronary and peripheral disease. $BSX

[Boston Scientific EMEA - Cardiology @BSC_EU_Heart]

Have you already submitted your IVUS-guided case applying WOLVERINE™ ? If you haven’t, #ShowUsYourCuttingEdge by showcasing your case for a chance to be part of the #EuroPCR 2025 expert talk.

Learn how to participate here: https://t.co/WMqj3aYVmu

#BSCEMEA #ModernPCI

[Martin Drew @martindrew42]

How would you like a chance to present your case at EuroPCR?
Have I captured your interest?
Click below to find out more… #ShowUsYourCuttingEdge

[Boston Scientific EMEA - Cardiology @BSC_EU_Heart]

Have you already shared your WOLVERINE™ case with us? If not, #ShowUsYourCuttingEdge by submitting your IVUS-guided WOLVERINE™ case for a chance to be part of the #EuroPCR 2025 expert talk.

Discover how to participate here: https://t.co/s1pqrqEZbw

[Boston Scientific EMEA - Cardiology @BSC_EU_Heart]

Have you already shared your WOLVERINE™ case with us? If not, #ShowUsYourCuttingEdge by submitting your IVUS-guided WOLVERINE™ case for a chance to be part of the #EuroPCR 2025 expert talk.

Discover how to participate here: https://t.co/s1pqrqEZbw